+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Skin Hives Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 471 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106032
The global market for Skin Hives Treatment was estimated at US$2.9 Billion in 2024 and is projected to reach US$4.4 Billion by 2030, growing at a CAGR of 7.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Skin Hives Treatment market.

Global Skin Hives Treatment Market - Key Trends & Drivers Summarized

Why Is the Management of Skin Hives Evolving From Symptom Control to Etiology-Specific Approaches?

Skin hives, or urticaria, are transient eruptions characterized by raised, itchy welts resulting from histamine release in the dermis. Historically managed with first-generation antihistamines and topical steroids, treatment paradigms for hives have shifted toward targeted, evidence-based protocols that distinguish between acute (lasting less than six weeks) and chronic (lasting six weeks or more) forms. This shift is being driven by a growing understanding of immunological mechanisms, such as autoantibodies, mast cell hypersensitivity, and external triggers like infections, allergens, or stress. As chronic urticaria becomes more prevalent, particularly in urban, high-stress populations, dermatologists and allergists are increasingly adopting stepwise treatment algorithms involving newer-generation therapies.

Acute hives typically resolve with non-sedating H1-antihistamines like cetirizine, loratadine, or fexofenadine. However, chronic spontaneous urticaria (CSU) and inducible urticaria require escalation to higher antihistamine doses, H2 blockers, leukotriene antagonists (montelukast), or biologics such as omalizumab (anti-IgE monoclonal antibody). This movement toward precision management is improving symptom control and reducing recurrence. Additionally, the use of diagnostic tools such as autologous serum skin tests (ASST), patch testing, and basophil activation tests is supporting individualized treatment and identifying refractory or autoimmune-driven cases.

How Are Biologics and Targeted Therapies Reshaping the Treatment Landscape?

Biologics are revolutionizing chronic urticaria treatment, particularly for patients unresponsive to antihistamines. Omalizumab, originally developed for asthma, has shown strong efficacy in CSU, reducing flare frequency and improving quality of life. It works by binding to free IgE, thereby preventing activation of mast cells and basophils. Its use is now recommended in step 3 of urticaria treatment guidelines by EAACI/GA²LEN/WAO. Ongoing clinical trials are investigating other biologics-such as dupilumab (IL-4 receptor inhibitor) and ligelizumab (a next-gen anti-IgE antibody)-to target downstream inflammatory pathways more precisely.

The appeal of biologics lies in their favorable side effect profiles, long dosing intervals, and rapid action. However, high costs and limited access remain barriers in many low- and middle-income countries. To address this, biosimilars and subcutaneous formulations with better affordability and administration convenience are being developed. Parallel efforts in repurposing immunomodulators like cyclosporine A for severe CSU are extending treatment options, especially in settings with limited biologics access.

In the over-the-counter segment, formulations containing antihistamines, calamine, aloe vera, and menthol are being optimized for faster onset and longer-lasting relief. Topical delivery systems-such as transdermal patches and lipid-based creams-are being engineered to enhance skin penetration while minimizing systemic absorption. These innovations are expanding the therapeutic arsenal for patients with mild or transient hives seeking immediate symptom control without systemic medication.

Which Patient Demographics and Environmental Factors Are Influencing Treatment Demand?

Urticaria affects individuals of all ages, but chronic forms are more commonly reported among adults aged 20-50, with a notable prevalence among women. Hormonal changes, autoimmune predispositions, and stress-related triggers contribute to gender and age-related disease patterns. Pediatric urticaria is often acute, related to viral infections, food allergies, or vaccines, and is typically managed with weight-adjusted antihistamines and avoidance strategies. The need for child-friendly liquid formulations and non-drowsy options is driving innovation in pediatric hives treatment products.

Urbanization, pollution, and climate variability are also contributing to hives outbreaks. Airborne allergens, food additives, UV exposure, and thermal changes are increasingly recognized as triggers, especially for chronic inducible urticaria. In industrialized nations, rising awareness and early diagnosis are translating into higher prescription volumes for both first-line and advanced therapies. Conversely, in emerging markets, underdiagnosis, lack of insurance coverage, and preference for traditional remedies are influencing care-seeking behavior and limiting access to modern treatments.

Psychodermatological correlations-such as anxiety, sleep disruption, and depression-are gaining recognition in chronic urticaria cases. As a result, integrative care models combining dermatology with behavioral health are being piloted, especially in tertiary centers. Lifestyle management strategies, including stress reduction, elimination diets, and allergen avoidance, are increasingly recommended alongside pharmacotherapy to address root causes and reduce flare frequency.

What Forces Are Driving Global Growth in the Skin Hives Treatment Market?

The growth in the global skin hives treatment market is driven by several factors including the rising incidence of chronic urticaria, expanded biologic approvals, and growing awareness of allergy-related skin disorders. Global lifestyle changes, increasing pollution, and dietary additives are contributing to higher disease prevalence, particularly in urban environments. Concurrently, improved patient education and dermatologist outreach campaigns are enabling earlier diagnosis and intervention.

Market expansion is also being fueled by advancements in dermatology-focused telehealth, e-pharmacy access to antihistamines, and the inclusion of hives treatment in digital health applications. These platforms are enabling prescription renewals, flare tracking, and symptom diaries-improving long-term disease monitoring and treatment compliance. Insurance coverage of biologics in high-income regions and expanded regulatory approval pipelines are making advanced therapies accessible to more patients.

The market is also witnessing significant activity from pharmaceutical manufacturers developing next-generation monoclonal antibodies, topical delivery platforms, and dual-action antihistamines. Consumer brands are leveraging botanicals, colloidal oatmeal, and herbal antihistamines in clean-label OTC products targeting mild hives relief. With dermatological awareness, biological innovation, and personalized treatment protocols continuing to evolve, the skin hives treatment market is positioned for robust and sustained global expansion.

Scope Of Study:

The report analyzes the Skin Hives Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Type (Chronic Hives, Acute Hives); Treatment (Anti-Inflammatory Drugs Treatment, Anti-Itch Drugs Treatment, Antihistamines Treatment, Other Treatments); Administration Route (Oral Administration, Topical Administration, Parenteral Administration); Distribution Channel (Hospital Pharmacies, Online Distribution Channel, Retail Pharmacies)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Chronic Hives segment, which is expected to reach US$3.3 Billion by 2030 with a CAGR of a 8.3%. The Acute Hives segment is also set to grow at 5.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $785.8 Million in 2024, and China, forecasted to grow at an impressive 11.7% CAGR to reach $939.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Skin Hives Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Skin Hives Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Skin Hives Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AstraZeneca, Allakos Inc., Amgen Inc., Celldex Therapeutics, Escient Pharmaceuticals and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Skin Hives Treatment market report include:

  • AstraZeneca
  • Allakos Inc.
  • Amgen Inc.
  • Celldex Therapeutics
  • Escient Pharmaceuticals
  • Eli Lilly and Company
  • Genentech (Roche)
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Otsuka Holdings
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • UCB Pharma
  • Wockhardt Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Skin Hives Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Chronic and Idiopathic Urticaria Spurs Demand for Targeted Therapies
  • Increased Availability of OTC Antihistamines and Topical Agents Expands Consumer Access
  • OEM Development of Biologics and Monoclonal Antibodies Enhances Treatment Precision
  • Growing Prevalence of Autoimmune and Allergic Conditions Drives Long-Term Medication Use
  • Healthcare Campaigns and Allergy Awareness Weeks Elevate Public Engagement and Diagnosis
  • Surge in Digital Symptom Trackers Encourages Timely Treatment and Medication Adherence
  • Expanded Use of Combination Therapies Improves Patient Quality of Life Metrics
  • Demand for Fast-Acting and Non-Sedative Formulations Strengthens Retail Market Penetration
  • Pharmaceutical Advances in H1 and H2 Antihistamines Promote Customized Regimens
  • Growth of Home-Based Allergy Management Tools Drives Telemedicine Consultations
  • OEM Partnerships With Research Institutions Accelerate Biologic Pipeline for Severe Hives
  • Rise in Organic and Herbal Alternatives Broadens Portfolio of Natural Treatment Options
  • Direct-to-Consumer Campaigns by Dermatology Brands Increase Product Visibility
  • Regulatory Approval of Novel Immunomodulators Spurs Competitive Differentiation
  • Global Climate Change and Pollution Levels Influence Allergen Exposure and Triggers
  • Increased Use of Mobile Health Apps Enhances Patient Reporting and Physician Monitoring
  • Emphasis on Pediatric-Friendly Formulations Expands Adoption in Children
  • Focus on Preventive Skin Care Products Strengthens Adherence for Recurrent Cases
  • Improved Clinical Trials for Chronic Urticaria Drives Better Efficacy Metrics
  • Healthcare Provider Education Initiatives Improve Diagnosis Accuracy and Early Intervention
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Skin Hives Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Skin Hives Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Skin Hives Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Skin Hives Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Hives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chronic Hives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Chronic Hives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Acute Hives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Acute Hives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Acute Hives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Anti-Inflammatory Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Anti-Inflammatory Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Anti-Itch Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Anti-Itch Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Anti-Itch Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Antihistamines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Antihistamines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Antihistamines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Skin Hives Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca
  • Allakos Inc.
  • Amgen Inc.
  • Celldex Therapeutics
  • Escient Pharmaceuticals
  • Eli Lilly and Company
  • Genentech (Roche)
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Otsuka Holdings
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • UCB Pharma
  • Wockhardt Ltd.

Table Information